Editorial Note on Discovery of Biomarkers

Priyanka Dubey^*
*Correspondence: Priyanka Dubey, Department of Genomics, Hamdard Institute of Medical Sciences and Research, New Delhi, India, Tel: 9336481948, Email:

Editorial

Biomarker discovery is a medical phrase that refers to the process of finding biomarkers. Biomarkers are routinely used blood tests in medicine. The pharmaceutical industry is interested in biomarker discoveries; blood tests or other biomarkers might be used as intermediate indicators of illness in clinical trials and as potential medication targets.

The method by which these tests were discovered can be considered biomarker discovery, though their identification has largely been done one at a time. Many well-known tests have been established based on biological understanding from domains such as physiology or biochemistry; as a result, only a few markers have been evaluated at a time. New molecular biologic approaches, which promise to uncover useful biomarkers quickly without requiring deep knowledge of disease processes, have generated renewed interest in biomarker development. A parallel method can be attempted by screening a large number of potential biomolecules at once; genomics and proteomics are two technologies employed in this procedure. Secretomics has also emerged as a key tool in the high-throughput search for biomarkers; nevertheless, there are still substantial technical challenges. The discovery of clinically relevant protein biomarkers of phenotypic and biological function is a growing field of study that will improve diagnostic skills.

The use of new and complicated technologies is enhancing biomarker discovery and development, offering optimism that additional clinical uses of biomarkers will be employed to improve diagnosis, prognosis, and disease monitoring. However, there is still room for advancement in terms of biomarker discovery automation and validation for clinical usage. The approval of diagnostic tests based on proven biomarkers by regulatory authorities such as the FDA and EMEA should always be considered when making judgments. It is critical that identified biomarkers get from the laboratory to the clinic, and more coordination between scientists and policymakers is necessary to achieve this.